Form 4: Adverum Director's Options Cancelled Post-Eli Lilly Merger

Adverum Biotechnologies Director Soo Hong's stock options were cancelled following the company's merger with Eli Lilly and Company's subsidiary, Flying Tigers Acquisition Corporation.

Summary

• Adverum Biotechnologies, Inc. was acquired by Eli Lilly and Company (Parent) through its direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation (Purchaser), via a tender offer and subsequent merger.
• The merger became effective on December 9, 2025, with Adverum continuing as the surviving entity and a wholly-owned subsidiary of Parent.
• Tendering stockholders received $3.56 per share in cash (Cash Consideration) and one non-tradable contingent value right (CVR).
• Each CVR represents the contractual right to receive up to two contingent cash payments, totaling up to an aggregate of $8.91 per CVR, upon the achievement of specified milestones.
• Company Stock Options with an exercise price equal to or greater than the Cash Consideration (Out-of-the-Money Options) were fully vested prior to the merger and then cancelled for no consideration.
• Stock options with an exercise price less than the Cash Consideration (Cash-Out Stock Options) were automatically cancelled in exchange for a cash payment (Cash Consideration minus exercise price) and one CVR for each share subject to the option.
• Reporting Person Soo Hong, a Director, had a total of 32,970 stock options cancelled as a result of the merger, with beneficial ownership of derivative securities now at zero.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a previously announced merger, which provides liquidity to shareholders and certain option holders, along with potential future value through CVRs. While some options were cancelled for no consideration, this was part of the pre-defined merger terms.

Positives

• Adverum Biotechnologies shareholders and certain option holders received liquidity through the cash consideration of $3.56 per share.
• The contingent value rights (CVRs) offer former shareholders and certain option holders potential future cash payments of up to $8.91 per CVR upon milestone achievement.
• Out-of-the-Money Options were fully vested prior to their cancellation, providing clarity on their status.

Negatives

• Stock options with exercise prices of $13.5, $15.6, and $7.32 (Out-of-the-Money Options) were cancelled for no consideration.
• The reporting person's beneficial ownership of derivative securities in Adverum Biotechnologies is now zero.

Risks

• Contingent value rights (CVRs) are non-tradable and their value is dependent on the achievement of specified milestones, introducing uncertainty regarding future payments.

Future Outlook

Former Adverum shareholders and certain option holders may receive future contingent cash payments up to $8.91 per CVR upon the achievement of specified milestones, as outlined in the CVR Agreement.

Industry Context

The acquisition of Adverum Biotechnologies by Eli Lilly reflects a common trend in the pharmaceutical industry where larger companies acquire smaller biotech firms to expand their pipeline or integrate specialized technologies. The use of contingent value rights (CVRs) is a mechanism often employed in such deals to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The use of CVRs in M&A transactions, particularly in the biotech sector, is a recognized strategy to manage risk and reward for pipeline assets, similar to deals involving companies like Sarepta Therapeutics or BioMarin Pharmaceutical where milestone payments are tied to clinical or regulatory success.
• The cash consideration of $3.56 per share, combined with potential CVR payments up to $8.91, provides a total potential value of $12.47 per share, which can be compared to recent biotech acquisitions on a per-share or enterprise value basis, considering the stage of Adverum's pipeline.

Corporate Governance

Related Party Transactions

• The merger between Adverum Biotechnologies, Inc. and Eli Lilly and Company's subsidiary constitutes a related party transaction where the issuer became a wholly-owned subsidiary of the acquirer.

Stakeholder Impact

• Shareholders: Received cash consideration and contingent value rights (CVRs), providing liquidity and potential future value.
• Option Holders (including employees and management): Options were either cancelled for no consideration (out-of-the-money) or exchanged for cash and CVRs (cash-out options), aligning with the merger terms.

Next Steps

• Achievement of specified milestones for contingent value right (CVR) payments.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, merger, acquisition, Form 4, stock options, CVR, contingent value rights, beneficial ownership